FINWIRES · TerminalLIVE
FINWIRES

ファーマコープRxが8つの薬局を2420万ドルで買収

By

-- ファーマコープRx(PCRX.V)は木曜日、カナダ東部にあるファーマチョイス・カナダ傘下の薬局8店舗を2,420万ドルで買収することに合意したと発表した。 声明によると、この買収は既存の手元資金で賄われ、ファーマコープの事業展開地域と規模を拡大する。すべての店舗は、既存の薬剤師が引き続き運営する。 買収は60日以内に完了する見込み。 ファーマコープはまた、モレル薬局4店舗の買収に関する拘束力のない合意書にも署名した。これらの買収は、完了すれば今後2四半期以内に完了する見込み。 アラン・シンプソン会長は、「今回の買収は、当社の買収戦略の継続的な実行と、当社の調達ネットワークの強さを反映するものだ」と述べた。 「主要都市圏にこれらの拠点が集中していること、そして経験豊富な薬剤師陣が継続的に在籍していることが、当社が効率的な統合を実現しつつ、強固な地域関係と優れた業績を維持できる基盤となっています。当社は、買収プロセスの初期段階から関与できる機会が増えており、評価、統合、そして長期的な価値創造に対する当社の規律あるアプローチに合致する買収案件を厳選して追求することが可能になっています。」 ファーマコープの株価は、トロント証券取引所ベンチャー市場で0.07ドル高の0.50ドルで取引を終えました。

Related Articles

Research

Research Alert: CFRA Reiterates Sell Opinion On Shares Of Hilton Worldwide Holdings Inc

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target by $9 to $293, or 32x our 2026 EPS estimate (unchanged) and in line with shares' five-year average forward multiple. We raise our 2026 EPS estimate to $9.16 from $8.88 and lower 2027's to $10.03 from $10.20. Following Q1 results that beat expectations and included raised guidance, we maintain our 2-STARS (Sell) rating. U.S. RevPAR performance broadened from primarily luxury and upper upscale segments to include more meaningful midscale contribution, which management attributes to the return of middle- and low-income consumers. However, we note Q1 results also included ADR deceleration, particularly among luxury hotels, which historically drive significant profit contribution. HLT's Q2 EBITDA guidance of $1,015-$1,035 million being below the $1,081 million consensus suggests luxury pricing power is weakening faster than midscale volume can offset. While the broadening demand trend is positive, we believe slowing luxury tailwinds limit upside at current valuation levels.

$HLT
Research

Research Alert: CFRA Maintains Buy Rating On Shares Of Universal Health Services

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $200 from $243, reflecting an 8.7x multiple of our 2026 EPS estimate, below peer multiples and a discount to UHS's five-year historical forward average of 11.9x. We lower our 2026 EPS forecast to $22.95 from $23.39 and cut our 2027 view to $25.48 from $25.67. Q1 inpatient volumes were flat on a same-facility basis, with seasonal headwinds from unfavorable winter weather and a milder flu/respiratory illness period. The recent expiration of ACA EPTCs also posed challenges, as UHS estimates a near 5% drop in ACA adjusted admissions relative to Q1 2025. UHS maintained its prior forecast of a 25%-30% decline in ACA exchange volumes during the full year, which represented around 6% of the acute care business adjusted admissions in 2025 and under 5% of the acute care segment revenues. UHS anticipates a $75M pre-tax earnings hit in 2026 from these developments, unchanged from prior guidance.

$UHS
Asia

Shenghe Resources' Q1 Profit Jumps 94%, Revenue Climbs 13%

Shenghe Resources' (SHA:600392) net profit attributable to shareholders in the first quarter jumped 94% to 327.3 million yuan from 168.3 million yuan a year earlier, according to a Shanghai bourse filing on Thursday.Earnings per share rose year on year to 0.1867 yuan from 0.0960 yuan.The Chinese rare earth miner's operating revenue climbed 13% to 3.38 billion yuan from 2.99 billion yuan in the previous year.

$SHA:600392